Addendum
Sotorasib (NSCLC) – Addendum to Commission A23-06
Report documents
-
Addendum
Sotorasib (NSCLC) – Addendum to Commission A23-06
Dossier assessment
Indication:
Adults with advanced non-small cell lung cancer with KRAS G12C mutation who have progressed after at least one prior line of systemic therapy
Result of dossier assessment:
Unchanged after addendum
- After first-line therapy with cytotoxic chemotherapy: added benefit not proven
- After first-line therapy with a PD-1/PD-L1 antibody in combination with platinum-containing chemotherapy or after sequential therapy with a PD-1/PD-L1 antibody and platinum-containing chemotherapy: added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2023-08-03 A G-BA decision was published.
G-BA documents on this decision
Project details
- Project no.
- A23-53
- Commission
- Commission awarded on 06.06.2023 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
Connected Projects
-
Dossier assessment
Sotorasib (NSCLC) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed